Fennec Pharmaceuticals Inc. Securities Litigation

If you purchased a significant amount of shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Fennec Pharmaceuticals Inc.
Date Filed:September 3rd, 2020
Sector:Health Care
Industry:Biotechnology: Biological Products (No Diagnostic Substances)
Class Start Date:February 11th, 2020
Class End Date:August 10th, 2020

According to the Complaint, Fennec Pharmaceuticals Inc. is a biopharmaceutical company that purportedly focuses on the development of PEDMARK, a sodium thiosulfate anhydrous injection, for the prevention of platinum-induced ototoxicity in pediatric cancer patients.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) that, as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Fennec Pharmaceuticals Inc.

 
First Identified Complaint

Jim Chapman, et al. v. Fennec Pharmaceuticals Inc., et al.

Date Filed:September 3rd, 2020
Class Period Start:February 11th, 2020
Class Period End:August 10th, 2020
First Identified Complaint Filings
#Document TitleFiling Date